Future challenges in the elimination of bacterial meningitis

Future challenges in the elimination of bacterial meningitis

Author Bottomley, Matthew J. Google Scholar
Serruto, Davide Google Scholar
Palazzi Safadi, Marco Aurelio Google Scholar
Klugman, Keith P. Google Scholar
Institution Emory Univ
Novartis Vaccines & Diagnost Srl
Universidade Federal de São Paulo (UNIFESP)
Univ Witwatersrand
Abstract Despite the widespread implementation of several effective vaccines over the past few decades, bacterial meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis and Group B Streptococcus (GBS) still results in unacceptably high levels of human mortality and morbidity. A residual disease burden due to bacterial meningitis is also apparent due to a number of persistent or emerging pathogens, including Mycobacterium tuberculosis, Escherichia coli, Staphylococcus aureus, Salmonella spp. and Streptococcus suis. Here, we review the current status of bacterial meningitis caused by these pathogens, highlighting how past and present vaccination programs have attempted to counter these pathogens. We discuss how improved pathogen surveillance, implementation of current vaccines, and development of novel vaccines may be expected to further reduce bacterial meningitis and related diseases in the future. (C) 2011 Elsevier B.V. All rights reserved.
Keywords Meningococcus
Language English
Sponsor Novartis Vaccines
Date 2012-04-30
Published in Vaccine. Oxford: Elsevier B.V., v. 30, p. B78-B86, 2012.
ISSN 0264-410X (Sherpa/Romeo, impact factor)
Publisher Elsevier B.V.
Extent B78-B86
Origin http://dx.doi.org/10.1016/j.vaccine.2011.12.099
Access rights Closed access
Type Article
Web of Science ID WOS:000305109700014
URI http://repositorio.unifesp.br/handle/11600/34808

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account